在癌症查试验中的死亡率的替代终点
1BioPharma Business & Europe, GRAIL Bio UK Ltd., London, UK.
Molecular oncology
|July 6, 2024
概括
癌症查试验需要比死亡率更快的结果测量. 像早期癌症阶段诊断和治疗资格等替代指标可以加速对新技术的评估,例如多种癌症早期检测测试.
科学领域:
- 在瘤学瘤学.
- 临床试验 临床试验
- 生物统计学 生物统计学
背景情况:
- 传统的癌症查试验依赖于死亡终点,这可能会推迟评估新技术的真正好处.
- 加快患者和公共利益需要更快地评估查干预措施.
研究的目的:
- 探索癌症查试验的替代终点,以便更快地评估新技术.
- 支持加快对多种癌症早期检测 (MCED) 试验的评估.
主要方法:
- 对癌症查试验终点选择当前实践的审查.
- 确定可在死亡率之前测量的替代指标.
- 建议创新的试验设计,结合这些早期的终点.
主要成果:
- 死亡终点通常太慢,无法评估快速发展的查技术.
- 替代终点包括晚期癌症发病率的降低和治疗治疗的资格.
- 早期可测量的终点可以补充传统的死亡率指标.
结论:
- 使用早期终点的创新试验设计对于实现MCED等新检测技术的好处至关重要.
- 采用替代指标可以加速将查进步转化为患者和公共卫生收益.
相关概念视频
Cancer Survival Analysis
340
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
340
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
125
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
125
Kaplan-Meier Approach
123
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
123
Comparing the Survival Analysis of Two or More Groups
175
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
175


